Court dismisses WuXi AppTec's 1260H lawsuit after the delisting; Dec 18 OMB risk remains
WuXi AppTec (HKEX: 02359; SSE: 603259) said a U.S. court approved dismissal of its Section 1260H lawsuit on Nov 16, 2026, after a DoD removal effective Nov 10. OMB's Dec 18 BIOSECURE review remains open.
The U.S. Department of Defense (DoD) formally removed WuXi AppTec (HKEX: 02359; SSE: 603259) from its Section 1260H list of “Chinese military companies operating in the United States” via a November 10, 2026 Federal Register notice (FR Doc. 2026-22840, docket DOD-2026-OS-2410). On November 17, 2026 the company said the lawsuit seeking that removal has now been dismissed: a voluntary announcement states that the U.S. District Court for the District of Columbia approved a joint stipulation of dismissal on November 16, 2026 (U.S. time). The Federal Register notice still preserves DoD’s right to relist WuXi on supplementary grounds, and it leaves open a separate U.S. Office of Management and Budget (OMB) national-security review under the BIOSECURE Act due by December 18, 2026.
For Western pharma procurement and legal teams, the distinction is unchanged by the dismissal. Removal from Section 1260H closes one statutory pathway to federal contracting restrictions. It does not close the BIOSECURE exposure.
The removal case is dismissed; Pathway 2 is not
DoD originally added WuXi AppTec to the Section 1260H list on June 8, 2026 (published June 10), citing a one-sentence rationale alleging indirect state ownership and military ties, according to a November 2026 legal analysis by Ropes & Gray. WuXi sued in the U.S. District Court for the District of Columbia on June 11 and won a preliminary injunction on August 7 barring DoD from enforcing the designation after the court found WuXi likely to succeed on claims that the listing was arbitrary and capricious.
In FR Doc. 2026-22840 (dated November 5 and published November 10), DoD confirmed that the Deputy Secretary of Defense/War delisted WuXi AppTec “in compliance with the order issued by the U.S. District Court of Columbia on August 7, 2026,” while explicitly stating the removal is “without prejudice to relisting the entity on additional or supplementary grounds.” In its November 10 HKEX announcement, WuXi said the decision relieves the company from further adverse consequences of the 1260H designation.
The November 17 announcement adds the procedural close. WuXi said it received DoD’s formal notice and that the removal took effect on November 10, 2026 (U.S. time). The company and DoD filed the joint stipulation on November 13, 2026 (U.S. time), and the court approved it on November 16. The filing does not give a court docket number, and it does not say the December 18 OMB process has stopped.
Under the BIOSECURE Act, Section 1260H is only one of two routes into “biotechnology company of concern” (BCC) status:
- Pathway 1 (closed for this listing): Requires appearance on the Section 1260H list plus involvement in biotechnology equipment or services. The case seeking removal of this listing is dismissed. Unless DoD builds a new administrative record that survives judicial review, WuXi cannot be named a BCC via this route.
- Pathway 2 (still active): Empowers OMB, through an interagency process, to designate an entity controlled by or operating on behalf of a foreign adversary government if it poses a national security risk. As Fierce Pharma noted, OMB’s initial BCC determination deadline falls on December 18, 2026—and WuXi General Counsel Howard Wu told investors on the company’s earnings call last month that WuXi had not yet received notice from OMB, though statutory notification and appeal steps remain ahead.
Next evidence triggers
- December 18, 2026 OMB deadline: Whether OMB publishes an initial BIOSECURE BCC list naming WuXi AppTec (or other Chinese CRDMOs) under Pathway 2, or issues formal pre-designation notices.
- Any new Section 1260H listing built on a fresh administrative record. The removal lawsuit over the June 2026 listing is no longer pending.
- Global sponsor contracting disclosures in Q4 2026 and Q1 2027 SEC/HKEX filings showing whether multi-year CDMO backlog growth continues normalizing or shifts toward ex-China dual-sourcing.
Updated November 17, 2026: Added WuXi’s announcement that the District Court approved dismissal of the 1260H removal suit on November 16 (U.S. time), after a removal the company says took effect November 10. The December 18 OMB checkpoint is unchanged.